Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...

US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn). The ...

TOKYO (Reuters) -U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory ...

Bain Capital is making its latest biotech bid in Japan, where it plans to acquire Mitsubishi Tanabe Pharma Corp. The Boston-based private investment firm is buying Tanabe Pharma from Mitsubishi ...

Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease.

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

Mitsubishi Tanabe Pharma and bluebird bio were both bought by investors during the month, while private equity firms ...

We believe this will provide hopeful options for patients around the world.” To find out more, visit Mitsubishi Tanabe Pharma.